What is Cybin?
Cybin is a Canadian-founded biotechnology company established in 2019, dedicated to creating safe and effective therapeutics for a range of mental health issues. Operating across Canada, the United States, the United Kingdom, the Netherlands, and Ireland, Cybin leverages a network of world-class partners and scientists. The company's core mission is to advance psychedelics into therapeutics through proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and tailored treatment regimens. Its focus on ethical biotechnology positions it as a key player in the evolving landscape of mental healthcare solutions.
How much funding has Cybin raised?
Cybin has raised a total of $80M across 2 funding rounds:
Share Placement
$30M
Debt
$50M
Share Placement (2023): $30M, investors not publicly disclosed
Debt (2025): $50M, investors not publicly disclosed
What's next for Cybin?
With a major enterprise-level funding context and a recent strategic investment, Cybin is poised for accelerated growth and development. The company is likely to expand its research and development initiatives, potentially scaling up clinical trials for its proprietary drug discovery platforms and novel treatment regimens. This strategic financing will enable Cybin to further its mission of progressing psychedelics to therapeutics, aiming to address unmet needs in mental health treatment and solidify its market position in the biotechnology sector.
See full Cybin company page
